Biotech

All Articles

Lilly experiences stage 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party commemorating the commendation of Alzh...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of notable leadership hirings, shootings an...

Lykos will definitely ask FDA to reconsider its own decision adhering to turndown of MDMA therapy for post-traumatic stress disorder

.Adhering to an unsatisfactory showing for Lykos Therapeutics' MDMA prospect for trauma at a recent ...

AN 2 fifty percents head count, ceases period 3 trial after records disappoint

.AN2 Therapies is reconsidering its own service in action to dull midphase records, vowing to lay of...

Merck pays out $700M for bispecific, snooping autoimmune opening as well as opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is paying out $700 million beforehand to test Amgen in a blood stream cancer market....

Gilead pays for J&ampJ $320M to leave licensing deal for seladelpar

.With Gilead Sciences about to an FDA decision for its liver disease medication seladelpar, the prov...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks may see the business setting up camping tents at basecamp behind Eli Lilly in an ef...

Entero giving up workers, vacating office and also stopping R&ampD

.Mattress Liquidators has actually turned Entero Therapeutics white colored as a piece. The collecto...

Exelixis drops ADC after choosing it's no suit for Tivdak

.Exelixis is giving up on its own tissue element (TF)- targeting antibody-drug conjugate after endin...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 full weeks after Roche's Genentech device ignored an SHP2 prevention deal, Relay Therapy has conf...